If everything works out, H. Lundbeck A/S (OTCPK:HLUYY) is going to be one of the best European mid-cap drug stocks over the next couple of years. If a few key programs fail to work out, though, it's going to be hard to justify even today's price, let alone a higher one. That puts Lundbeck squarely into an investing grey zone, as the risk and reward are much higher than for a typical pharmaceutical company, but quite a bit less than for a true biotech.
I continue to be bullish on the company's outlook and prospects. Lundbeck is a CNS specialist, and one that has been clearly trying to learn from industry experience in depression, Alzheimer's, schizophrenia, and other...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|